Green Ribbon Joins NVIDIA Inception Program

Green Ribbon, a data-driven healthcare and insurtech innovation company, is gaining attention as it has been officially selected for NVIDIA Inception, a global AI innovation startup discovery and support program. NVIDIA Inception provides startups worldwide that are driving industrial innovation with AI and accelerated computing technologies a wide range of benefits including GPU and AI infrastructure, SDKs, developer training, and connections to global venture capitalists and pharmaceutical company networks. Green Ribbon, an AI platform company possessing the largest volume of real insurance and medical treatment data in Korea, helps with the refund of hidden insurance claims and medical expenses through its B2C service 'LifeCatch', and offers AI-based clinical trial subject recruitment and RWD (Real-World Data) analysis services through its B2B solution 'Green Scout'. In particular, Green Scout focuses on the inefficient patient recruitment problem, which accounts for over 80% of clinical trial delays and discontinuations. By maximizing recruitment success rates through AI scoring-based subject suitability assessment, precise indicator analysis, and optimal hospital recommendation algorithms, it actually demonstrated innovative results by proving over 120 times higher recruitment efficiency compared to conventional methods in a PoC with a multinational pharmaceutical company. Industry experts attach great significance to the fact that, through this NVIDIA Inception selection, Green Ribbon has simultaneously secured global AI infrastructure and a pharmaceutical company network for the first time among RWD-based platform companies in Korea. Kim Kyu-ri, CEO of Green Ribbon, emphasized, "In the new drug development process, which is often delayed by inefficient patient recruitment, Green Ribbon is implementing an innovative model where AI predicts and recommends suitable patients based on insurance and medical data." Leveraging its future collaboration with NVIDIA, Green Ribbon plans to advance its AI models, expand its global clinical trial network, and build a data-driven new drug development support ecosystem, thereby leaping forward as a key partner in the global pharmaceutical and biotechnology industry.